BIOCON

received FDA approval

Biologics received FDA approval for two denosumab biosimilars, Bosaya and Aukelso, with provisional interchangeability designation for broader market adoption. The approved biosimilars treat osteoporosis and multiple myeloma, with market potential despite Biocon's year-to-date 4% losses.